How UK healthcare works
The National Institute for Health and Care Excellence is the body that decides which new medicines, devices, and procedures the National Health Service is required to fund. Here is how those decisions are made, what they mean for patient access, and where the process has limits.
Dr Seth Rankin
MBChB MRCGP. Founder of LoveMyLife. Former NHS Commissioner and Managing Partner of Wandsworth Medical Centre.
23 April 2026
11 min read
When a new cancer drug, a new gene therapy, or a new biologic receives a UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), it is not automatically available on the National Health Service (NHS). It becomes a candidate for NHS use. Whether it is actually funded, for whom, and under what conditions, is decided separately by the National Institute for Health and Care Excellence (NICE).
NICE is the single most important gatekeeping body in UK healthcare for new treatments. Its decisions determine what the NHS is legally required to fund, which in turn determines which treatments are available free at the point of use to the UK population. This article sets out what NICE is, how it makes its decisions, what the statutory funding duty looks like in practice, and where the system has limits. Sources are at the end.
NICE was established in 1999 to end what was then known as the "postcode lottery": the phenomenon of the same NHS treatment being available in one part of the country and not the next, based on local commissioning decisions. It was set up as an independent public body sponsored by the Department of Health and Social Care (DHSC), with a remit to produce guidance on clinical and cost effectiveness that the NHS would then be required to follow.
It was originally called the National Institute for Clinical Excellence. Its remit expanded in 2005 to include public health guidance, and again in 2013 to include social care guidance, at which point it was renamed the National Institute for Health and Care Excellence. The acronym NICE was kept through both renames.
NICE's decisions are made by independent advisory committees drawn from clinicians, health economists, patient representatives, and methodological experts. Committee recommendations are published for public consultation before being finalised.
NICE issues several distinct categories of guidance, each with a different role in the NHS.
Technology appraisals (TAs) assess whether new medicines, devices, and procedures should be funded by the NHS. These carry a statutory funding duty (see below) and are the type of NICE guidance that most directly determines patient access to new drugs.
Clinical guidelines set out how specific conditions should be diagnosed and managed. These inform everyday clinical practice but are not legally binding in the same way as TAs.
Public health guidance covers population-level interventions, prevention, and behaviour-change programmes.
Highly specialised technologies (HST) guidance is a separate, more generous appraisal route for treatments for very rare conditions. It uses a higher cost-effectiveness threshold because the per-patient costs of treatments for rare diseases are typically very high and the market for them is small.
Medical technologies guidance, diagnostics guidance, and interventional procedures guidance cover devices, tests, and procedures outside the medicines route.
Quality standards set concise, measurable markers of high-quality care for specific conditions or care pathways.
Of these, the technology appraisal programme is the one that most directly determines which specific medicines a patient can access on the NHS.
The central tool NICE uses to decide whether a treatment is cost effective is the Quality-Adjusted Life Year, or QALY. A QALY is a standardised unit that combines how much extra time a treatment adds to a patient's life with the quality of that extra time. One year of full health equals one QALY. One year at 50 per cent of full health equals half a QALY, and so on.
A new treatment is compared with the existing standard of care on two axes: how much additional clinical benefit it produces, measured in QALYs, and how much additional cost it generates, measured in pounds. The ratio of those two, the incremental cost-effectiveness ratio (ICER), expresses the price the NHS is being asked to pay for each additional year of good-quality life the treatment delivers.
Treatments that deliver a QALY at a low cost are straightforwardly approved. Treatments that deliver a QALY at a very high cost face a harder threshold test.
For most of NICE's history, the reference threshold was £20,000 to £30,000 per QALY. A treatment whose ICER sat below £20,000 per QALY was generally approved. A treatment between £20,000 and £30,000 per QALY required additional justification. Above £30,000 per QALY, approval became progressively harder, though not impossible.
That threshold has just changed. From April 2026, NICE raised its cost-effectiveness threshold for the first time in twenty years, to £25,000 to £35,000 per QALY. The new range applies to technology appraisals going forward.
On top of the standard threshold, two specific uplifts apply.
End-of-life uplift. Treatments that extend life for patients with short life expectancy (defined narrowly in the NICE manual) can be approved at an ICER of up to around £50,000 per QALY.
Severity modifier. Treatments for conditions of high absolute and proportional severity can receive a multiplier (up to 1.7x) on the QALY benefit they generate, which effectively stretches the threshold further for these conditions.
The thresholds are a framework rather than a hard rule. The committee considers uncertainty in the evidence, population size, equity considerations, and the manufacturer's proposals before issuing a final recommendation.
For treatments aimed at very rare conditions, NICE uses a separate appraisal route with a higher threshold. The Highly Specialised Technologies (HST) programme considers treatments for conditions so rare that per-patient development costs are extreme and the national market is small.
The HST threshold starts at around £100,000 per QALY and can be weighted upward by a factor of up to 3 depending on how many QALYs the treatment delivers, giving an effective ceiling close to £300,000 per QALY for treatments that offer the largest QALY gains. A small number of gene therapies, enzyme-replacement therapies, and ultra-rare disease treatments have been funded on the NHS through this route at costs that would be unthinkable under the standard appraisal.
The HST framework is one of the more striking features of UK health technology assessment. It means that a UK patient with a rare disease can, in principle, receive a treatment costing hundreds of thousands of pounds per year, free at the point of use, if NICE has approved it through the HST route.
Most technology appraisals are delivered as Single Technology Appraisals (STAs), where NICE assesses one medicine or device for one indication. The manufacturer submits an evidence package; an independent academic group, the Evidence Review Group, critiques it; a NICE committee deliberates and issues a draft recommendation, which is consulted on and then finalised.
A smaller number of appraisals are Multi-Technology Appraisals (MTAs), in which several similar treatments are appraised together. MTAs take longer but are useful when the comparative picture between several drugs is itself the question.
NICE operates a fast-track route for treatments that are clearly highly cost effective. These are approved on an accelerated timeline and carry a shortened 30-day NHS funding duty.
For cancer treatments specifically, the Cancer Drugs Fund provides a managed-access route that allows a drug to be used on the NHS while further evidence is collected, with a reassessment at the end of a defined period.
NICE guidance is not just advisory. A recommendation in a technology appraisal triggers a statutory duty on NHS commissioners to fund the treatment. NHS commissioners are legally required to fund NICE-approved medicines normally within 90 days of final guidance, and within 30 days for a subset of fast-track appraisals.
The funding duty sits inside the NHS Constitution for England as a patient right. A patient in England whose clinical situation meets the criteria of a NICE-approved technology appraisal has a legal entitlement to access the treatment through the NHS.
In practice, this means that when NICE approves a new medicine, the NHS in England must make it available to the whole eligible patient population within a defined legal window, whatever the patient's income, insurance status, or postcode. This mechanism is one of the distinctive features of UK healthcare and is a large part of why UK patients gain population-level access to new treatments within a predictable timeline.
NICE guidance is national; NHS commissioning is local. Integrated Care Boards (ICBs) hold the local commissioning budget and apply NICE recommendations through their own formularies, referral pathways, and shared-care protocols.
ICBs cannot override a NICE technology appraisal. They can, however, shape how local services are organised around it: which hospital delivers the treatment, which clinician initiates prescribing, how shared care is arranged between specialist and primary care, and what monitoring is put in place.
For a patient, the practical consequence is that access to a NICE-approved treatment is legally guaranteed, but the route into it (which clinic, which specialist, how long the referral takes) can vary by ICB and by region.
NICE's reach is broad but not complete. Several categories of NHS decision sit outside its remit.
Specialised commissioning for some rare conditions and procedures is handled directly by NHS England through specialised commissioning panels, not through NICE.
Devolved nations. NICE guidance applies to England, with Scotland, Wales, and Northern Ireland running their own health technology assessment bodies. The Scottish Medicines Consortium (SMC) is the equivalent in Scotland; the All Wales Medicines Strategy Group covers Wales.
Off-label prescribing. NICE does not appraise off-label uses of medicines. These are managed through NHS England and local guidance.
Some very cheap generic medicines are used without NICE appraisal because the cost-effectiveness case is self-evident.
Most surgical innovation and procedural changes are developed outside the TA route, although NICE does issue interventional procedures guidance for newer procedures.
The categories of treatment where NICE has made the largest difference to population-level UK access are, broadly:
Cancer medicines. A long series of biologics, immunotherapies, targeted therapies, and CAR-T cell treatments have been approved through technology appraisal and, in some cases, through the Cancer Drugs Fund managed-access route. A patient with a qualifying cancer in England generally has the same access to modern oncology as a patient in a comparable country, without the insurance-coverage battles that feature in some other systems.
Hepatitis C antivirals. The direct-acting antiviral revolution of the mid-2010s was rolled out across the NHS population on the basis of NICE technology appraisals, at a cost that would have been unthinkable under older prescribing rules.
Gene therapies for rare diseases. Several gene therapies for rare genetic conditions have been approved through the HST route and made available to the whole UK eligible patient population.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, which have materially changed the clinical course of cystic fibrosis for many patients, have been funded on the NHS following NICE and managed-access agreements.
Biologics for inflammatory conditions including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and severe asthma have moved from specialist-only to routine availability following the NICE route.
GLP-1 weight-management medication for obesity has been appraised by NICE and is funded within defined criteria through specialist weight-management services.
These are categories, not promises. Individual patient access depends on meeting the clinical eligibility criteria of each specific appraisal and on the local ICB pathway.
A fair view of NICE includes three caveats.
Some treatments are rejected on cost-effectiveness grounds. A treatment approved abroad and used in other Western health systems can be unavailable on the NHS in England if NICE has concluded the cost per QALY is too high. These rejections are published and debated, and they are often the source of genuine patient distress.
The threshold is contested. The threshold range (£25,000 to £35,000 per QALY from April 2026, with higher uplifts for end-of-life and severity) is an empirical and political judgement, not a natural law. There is an ongoing academic and policy debate about whether the level is right.
The appraisal process takes time. A NICE single technology appraisal typically takes around twelve months from listing to final guidance, and longer for more complex multi-technology appraisals. A treatment that has received marketing authorisation may not be routinely available on the NHS for a year or more after that, unless it goes through the fast-track or Cancer Drugs Fund managed-access route.
None of these limits undermine the basic point that NICE is the mechanism by which the NHS in England offers consistent, universal, evidence-based access to new treatments. They describe the shape of the compromise between access, affordability, and evidence that any publicly funded system has to make.
For most patients, NICE operates in the background of NHS care. A GP prescribes what the local formulary allows, a hospital clinic offers what has been through NICE, and the patient does not need to think about the mechanism. The system is designed to be invisible when it is working.
Where it becomes visible is when a patient has heard about a new treatment (through patient groups, overseas clinicians, or private consultations) and wants to know whether they can access it on the NHS. The short version of the answer is usually:
If the treatment has a positive NICE TA for your clinical situation, you are legally entitled to NHS access, usually within 90 days of final guidance.
If the treatment is on a managed-access scheme, you may be able to access it now, with reassessment scheduled at a defined review point.
If the treatment has been rejected by NICE, NHS access is usually not available; the private or clinical-trial routes become the only options, and the cost can be very substantial.
If the treatment has not yet been appraised, NHS access depends on local commissioning, clinical-trial eligibility, and any individual funding-request route.
Your NHS GP, specialist, or prescribing pharmacist can check the current NICE status of any specific treatment, and the NICE website publishes the full catalogue of guidance at nice.org.uk.
NICE is the body that turns a marketing authorisation into an NHS funding duty. It uses the cost-per-QALY framework to weigh clinical benefit against cost, with a standard threshold of £25,000 to £35,000 per QALY (as of April 2026), an end-of-life uplift to about £50,000, a severity modifier, and a separate Highly Specialised Technologies route with a ceiling close to £300,000 per QALY for treatments for very rare conditions. A positive NICE recommendation triggers a 90-day statutory NHS funding duty, shortened to 30 days for fast-track approvals.
The mechanism is not perfect. Some treatments are rejected. The threshold is contested. Appraisals take time. But the effect of the system is that UK patients have universal, evidence-based, legally enforceable access to the treatments that NICE has approved, within a predictable timetable, paid for from general taxation. That is the specific thing the NHS model delivers that most private-insurance-led systems do not.
NICE, About us. Remit, structure, and history.
NICE, About technology appraisal guidance. The technology appraisal programme.
NICE, Highly specialised technologies guidance. The ultra-rare disease appraisal route.
NICE, Changes to NICE's cost-effectiveness thresholds confirmed. The 2026 threshold update.
gov.uk, Introducing new medicines in the NHS in the UK: pathway. The statutory NHS funding requirement.
gov.uk, NHS Constitution for England. Patient rights including access to NICE-approved treatments.
NHS England, Cancer Drugs Fund. Managed-access route for cancer medicines.
NHS England, Integrated Care Boards. Local application of NICE guidance.
Scottish Medicines Consortium, scottishmedicines.org.uk. Health technology assessment body for Scotland.
All Wales Medicines Strategy Group, awmsg.nhs.wales. Health technology assessment body for Wales.
MHRA, gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency. UK marketing-authorisation regulator.
Clinically reviewed
Dr Seth Rankin · MBChB MRCGP - Founder and Medical Director, LoveMyLife
Dr Seth Rankin qualified in medicine at Auckland School of Medicine in New Zealand in 1990 and worked as a junior doctor across New Zealand, Australia, and the UK before qualifying as a Member of the Royal College of General Practitioners (MRCGP) through the London Deanery in 2004. He was Managing Partner of Wandsworth Medical Centre from 2006 to 2016 and served as a Board Member of Wandsworth Clinical Commissioning Group for nine years. He is the founder of London Travel Clinic, London Doctors Clinic, London Medical Laboratory, and LoveMyLife.
If you have a question about whether a specific treatment is available on the NHS, or want to discuss a private alternative, we are happy to talk it through.
Begin your consultation at this link. Online or in person at Westfield London.